Steven Finkbeiner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4061970/publications.pdf Version: 2024-02-01

		87888	82547
72	13,756	38	72
papers	citations	h-index	g-index
123 all docs	123 docs citations	123 times ranked	25415 citing authors

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 2004, 431, 805-810.	27.8	1,814
3	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
4	Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein. Journal of Biological Chemistry, 2011, 286, 20710-20726.	3.4	499
5	In Silico Labeling: Predicting Fluorescent Labels in Unlabeled Images. Cell, 2018, 173, 792-803.e19.	28.9	473
6	Cytoplasmic Mislocalization of TDP-43 Is Toxic to Neurons and Enhanced by a Mutation Associated with Familial Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2010, 30, 639-649.	3.6	446
7	CREB Couples Neurotrophin Signals to Survival Messages. Neuron, 2000, 25, 11-14.	8.1	426
8	Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nature Chemical Biology, 2014, 10, 677-685.	8.0	368
9	Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5803-5808.	7.1	308
10	Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4697-4702.	7.1	301
11	Protein aggregates in Huntington's disease. Experimental Neurology, 2012, 238, 1-11.	4.1	283
12	A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16982-16987.	7.1	247
13	Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16889-16894.	7.1	236
14	Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nature Chemical Biology, 2011, 7, 925-934.	8.0	178
15	Huntington's Disease. Cold Spring Harbor Perspectives in Biology, 2011, 3, a007476-a007476.	5.5	177
16	Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD. Neuron, 2019, 103, 802-819.e11.	8.1	161
17	Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nature Chemical Biology, 2013, 9, 586-592.	8.0	157
18	Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis. Journal of Neuroscience, 2010, 30, 10541-10550.	3.6	149

STEVEN FINKBEINER

#	Article	IF	CITATIONS
19	Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System. Neuron, 2016, 92, 780-795.	8.1	137
20	Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson's Disease. PLoS ONE, 2014, 9, e87133.	2.5	126
21	Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies. Journal of Neuroscience, 2014, 34, 418-433.	3.6	124
22	Automated microscope system for determining factors that predict neuronal fate. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3840-3845.	7.1	120
23	Sending signals from the synapse to the nucleus: Possible roles for CaMK, Ras/ERK, and SAPK pathways in the regulation of synaptic plasticity and neuronal growth. Journal of Neuroscience Research, 1999, 58, 88-95.	2.9	117
24	Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7821-7826.	7.1	114
25	Assessing microscope image focus quality with deep learning. BMC Bioinformatics, 2018, 19, 77.	2.6	109
26	The Psychiatric Cell Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular Pathways in Neuropsychiatric Disorders. Cell, 2018, 174, 505-520.	28.9	108
27	Nrf2 mitigates LRRK2- and α-synuclein–induced neurodegeneration by modulating proteostasis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1165-1170.	7.1	95
28	Calcium regulation of the brain-derived neurotrophic factor gene. Cellular and Molecular Life Sciences, 2000, 57, 394-401.	5.4	86
29	Single Neuron Ubiquitin-Proteasome Dynamics Accompanying Inclusion Body Formation in Huntington Disease. Journal of Biological Chemistry, 2009, 284, 4398-4403.	3.4	84
30	Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cellular and Molecular Neurobiology, 2016, 36, 459-470.	3.3	75
31	Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases. Annual Review of Pharmacology and Toxicology, 2016, 56, 489-510.	9.4	72
32	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
33	Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neuroscience, 2022, 25, 226-237.	14.8	66
34	Bridging the Valley of Death of therapeutics for neurodegeneration. Nature Medicine, 2010, 16, 1227-1232.	30.7	54
35	A Compact Î ² Model of huntingtin Toxicity. Journal of Biological Chemistry, 2011, 286, 8188-8196.	3.4	53
36	Disease-Modifying Pathways in Neurodegeneration. Journal of Neuroscience, 2006, 26, 10349-10357.	3.6	51

Steven Finkbeiner

#	Article	IF	CITATIONS
37	Protein turnover and inclusion body formation. Autophagy, 2009, 5, 1037-1038.	9.1	49
38	High-content screening of primary neurons: ready for prime time. Current Opinion in Neurobiology, 2009, 19, 537-543.	4.2	47
39	Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease. Nature Communications, 2018, 9, 3191.	12.8	47
40	High-Throughput Screening in Primary Neurons. Methods in Enzymology, 2012, 506, 331-360.	1.0	40
41	Proteostasis in striatal cells and selective neurodegeneration in Huntingtonââ,¬â,,¢s disease. Frontiers in Cellular Neuroscience, 2014, 8, 218.	3.7	39
42	Cell-Based Screening: Extracting Meaning from Complex Data. Neuron, 2015, 86, 160-174.	8.1	37
43	The Arc of cognition: Signaling cascades regulating Arc and implications for cognitive function and disease. Seminars in Cell and Developmental Biology, 2018, 77, 63-72.	5.0	37
44	αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease. Human Molecular Genetics, 2016, 25, 1677-1689.	2.9	33
45	Automated four-dimensional long term imaging enables single cell tracking within organotypic brain slices to study neurodevelopment and degeneration. Communications Biology, 2019, 2, 155.	4.4	28
46	An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. IScience, 2021, 24, 103221.	4.1	27
47	An evaluation of specificity in activity-dependent gene expression in neurons. Progress in Neurobiology, 2002, 67, 469-477.	5.7	25
48	Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration. PLoS ONE, 2014, 9, e91608.	2.5	23
49	Cell death assays for neurodegenerative disease drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 901-913.	5.0	20
50	Targeting the low-hanging fruit of neurodegeneration. Neurology, 2014, 83, 1470-1473.	1.1	19
51	Persistent mRNA localization defects and cell death in ALS neurons caused by transient cellular stress. Cell Reports, 2021, 36, 109685.	6.4	18
52	Longitudinal measures of proteostasis in live neurons: Features that determine fate in models of neurodegenerative disease. FEBS Letters, 2013, 587, 1139-1146.	2.8	17
53	Egocentric and allocentric visuospatial working memory in premotor Huntington's disease: A double dissociation with caudate and hippocampal volumes. Neuropsychologia, 2017, 101, 57-64.	1.6	16
54	Longitudinal tracking of neuronal mitochondria delineates PINK1/Parkin-dependent mechanisms of mitochondrial recycling and degradation. Science Advances, 2021, 7, .	10.3	13

STEVEN FINKBEINER

#	Article	IF	CITATIONS
55	Genetically encoded cell-death indicators (GEDI) to detect an early irreversible commitment to neurodegeneration. Nature Communications, 2021, 12, 5284.	12.8	13
56	The Receptor-interacting Serine/Threonine Protein Kinase 1 (RIPK1) Regulates Progranulin Levels. Journal of Biological Chemistry, 2017, 292, 3262-3272.	3.4	12
57	Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease. Communications Biology, 2022, 5, 49.	4.4	10
58	Superhuman cell death detection with biomarker-optimized neural networks. Science Advances, 2021, 7, eabf8142.	10.3	10
59	Going Retro: Ancient Viral Origins of Cognition. Neuron, 2015, 86, 346-348.	8.1	9
60	Identification of hepta-histidine as a candidate drug for Huntington's disease by in silico-in vitro- in vivo-integrated screens of chemical libraries. Scientific Reports, 2016, 6, 33861.	3.3	9
61	Approaches to develop therapeutics to treat frontotemporal dementia. Neuropharmacology, 2020, 166, 107948.	4.1	9
62	The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. Journal of Cell Biology, 2022, 221, .	5.2	8
63	A Three-Groups Model for High-Throughput Survival Screens. Biometrics, 2016, 72, 936-944.	1.4	7
64	NUB1 snubs huntingtin toxicity. Nature Neuroscience, 2013, 16, 523-525.	14.8	6
65	RNA decay back in play. Nature Neuroscience, 2007, 10, 1083-1084.	14.8	5
66	Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease. Neurobiology of Disease, 2020, 146, 105088.	4.4	3
67	Generation of two human induced pluripotent stem cell lines from fibroblasts of unrelated Parkinson's patients carrying the G2019S mutation in the LRRK2 gene (LCSBi005, LCSBi006). Stem Cell Research, 2021, 57, 102569.	0.7	2
68	Transcriptional signatures in iPSC-derived neurons are reproducible across labs when differentiation protocols are closely matched. Stem Cell Research, 2021, 56, 102558.	0.7	2
69	Generation of two human induced pluripotent stem cell lines from fibroblasts of Parkinson's disease patients carrying the ILE368ASN mutation in PINK1 (LCSBi002) and the R275W mutation in Parkin (LCSBI004). Stem Cell Research, 2022, 61, 102765.	0.7	2
70	Sending signals from the synapse to the nucleus: Possible roles for CaMK, Ras/ERK, and SAPK pathways in the regulation of synaptic plasticity and neuronal growth. Journal of Neuroscience Research, 1999, 58, 88-95.	2.9	1
71	Single cell tracking based on Voronoi partition via stable matching. , 2020, , .		1
72	Generation of two human induced pluripotent stem cell lines (iPSCs) with mutations of the α-synuclein (SNCA) gene associated with Parkinson's disease; the A53T mutation (LCSBi003) and a triplication of the SNCA gene (LCSBi007). Stem Cell Research, 2021, 57, 102600.	0.7	0